Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT05521529 Recruiting - Cushing Syndrome Clinical Trials

Cushing's Syndrome Before and After Treatment (CORRECT)

CORRECT
Start date: February 16, 2023
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to prospectively study patients with Cushing's syndrome before and after treatment, with a special emphasis on physical function, quality of life, and circadian rhythms. The hypotheses are: - Cushing's syndrome negatively impacts health-related quality of life (HRQoL) and physical functioning - Cushing's syndrome is associated with altered circadian rhythms at the whole body level and in peripheral target tissues. - These complications partially reverse following disease control.

NCT ID: NCT05521451 Recruiting - Atrial Fibrillation Clinical Trials

Clinical Cohort Study - TRUST

TRUST
Start date: March 17, 2021
Phase:
Study type: Observational [Patient Registry]

The "Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg" (TRUST) study is an investor-initiated, single-center, prospective clinical cohort study including patients treated with cardiac arrhythmias or at high risk for cardiac arrhythmias. The design enables prospective, low-threshold, near complete inclusion of patients with arrhythmias treated at the UHZ. Collection of routine follow-up data, detailed procedural information and systematic biobanking will enable precise and robust phenotyping.

NCT ID: NCT05521438 Recruiting - Netherton Syndrome Clinical Trials

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

Start date: June 23, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle

NCT ID: NCT05519683 Recruiting - Clinical trials for Irritable Bowel Syndrome With Constipation

Home Transcutaneous Electrical Acustimulation (TEA)

Home-TEA
Start date: November 2, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This study will assess the efficacy of two active treatments with TEA and a chemical neuromodulator (escitalopram aka Lexapro) versus a sham comparator or control group on abdominal pain.

NCT ID: NCT05518864 Recruiting - Clinical trials for Bladder Pain Syndrome

GAG-therapy Efficacy Trial Solution for Bladder Pain Syndrome/ Interstitial Cystitis (GETSBI Study)

GETSBI
Start date: October 21, 2021
Phase: Phase 4
Study type: Interventional

Rationale: Efficacy study (RCT) for glycosaminoglycan(GAG)-therapy for the indication bladder pain syndrome / interstitial cystitis with Hunner lesion subtype (BPS-IC H+). reason for this study is a current lack of evidence regarding its efficacy and cost-effectiveness. Main objective is to determine short and long term efficacy of GAG therapy (bladder instillations) for people with BPS-IC H+ as compared to placebo treatment on dominant symptoms such as pain and Quality of Life (QOL)

NCT ID: NCT05518786 Recruiting - Clinical trials for Postintensive Care Syndrome

Precision Medicine for Post-Intensive Care Syndrome (PreMed4PICS)

PreMed4PICS
Start date: May 1, 2020
Phase:
Study type: Observational

Critically ill patients show an acute phase characterized by systemic spread of the inflammatory response, irrespectively of the cause of intensive care unit (ICU) admission, and late sequelae, including ICU acquired muscle weakness (ICUAW) and neurocognitive impairment. Mechanisms driving these late sequelae are unknown and there are no effective therapies to date. PreMed4PICS hypothesis is that skeletal muscle pathogenetic phenotypes and long-term sequelae in survivors to critical illness can be predicted at ICU admission in peripheral blood samples by transcriptomic profiling of the acute systemic response. Our main objective is to identify pathogenesis-dependent predictive signatures of muscle injury and clinical outcomes such as ICUAW or cognitive impairment. A multicentric prospective observational study will be conducted including adult patients admitted to the ICU and followed up until 12 months after ICU discharge. This will allow for clinical subphenotyping, sample acquisition and histopathological studies. To identify subphenotype-specific molecular pathways involved in skeletal muscle recovery, single-nuclei RNAseq will be performed. Massive sequencing of whole blood RNA and circulating microRNA at ICU admission will be performed to identify transcriptomic signatures that result in quantitative scores predictive of the outcomes of interest. All the findings will be confirmed in two validation cohorts. Collectively, this project aims to characterize the molecular mechanisms leading to ICUAW development and recovery, identifying therapeutic targets. The potential of a quantitative approach to the acute inflammatory response to predict long-term sequelae in survivors of critical illness will be validated.

NCT ID: NCT05514938 Recruiting - Clinical trials for Coronary Artery Disease

Polypill in Acute Coronary Syndrome

POLY-ACS
Start date: November 30, 2022
Phase: Phase 2
Study type: Interventional

Acute coronary syndromes (ACS) represent a major contributor to mortality, morbidity, and healthcare costs. Effective therapies are widely available; however, adherence is low. This contributes to worse patient outcomes and increased risk of morbidity and mortality. The once-daily polypill leverages a population-based strategy that has previously demonstrated efficacy in improving adherence and access to therapy in low-resource settings, making it an innovative approach for improving post-ACS care. This study aims to investigate the utility of a polypill-based strategy for patients with ACS with drug eluting stent (DES) placement. The polypill will consist of a high-intensity statin (rosuvastatin 40 mg daily), aspirin 81 mg daily, and either clopidogrel 75 mg or prasugrel 10 mg daily.

NCT ID: NCT05514483 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

5-HT3 Receptor Antagonist and Respiratory Drive in Patients With ARDS

DRIVE
Start date: November 10, 2022
Phase: Phase 4
Study type: Interventional

This is a pilot study aimed at acquiring primary physiological data, describing and estimating the effects of a 5-HT3 receptor antagonist (ondansetron) on respiratory drive in patients with acute respiratory distress syndrome (ARDS). The results of this study will determine the interest and feasibility of assessing the clinical applications of ondansetron in reducing patient self-inflicted lung injury (P-SILI) in ARDS, in subsequent studies.

NCT ID: NCT05509933 Recruiting - Clinical trials for Engraftment Syndrome

Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

Start date: November 9, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.

NCT ID: NCT05509725 Recruiting - Clinical trials for IBS - Irritable Bowel Syndrome

Efficacy and Safety of a Probiotic Formulation in Adults With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Start date: August 11, 2022
Phase: Phase 4
Study type: Interventional

The purpose of the study is to monitor safety and to evaluate the efficacy of a probiotic formulation on abdominal pain, abnormal defecation, comorbid mood disorders (anxiety and depression) as well as general quality of life in adults with IBS-D.